This report provides a comprehensive analysis of the global nucleic acid-based therapy market, projecting steady growth through 2032. It examines various therapeutic types, including antisense oligonucleotides, siRNA, and mRNA, across diverse applications such as neuromuscular diseases and COVID-19. By evaluating key regional markets and major industry players like Sarepta Therapeutics and Ionis Pharmaceuticals, the study highlights emerging opportunities, competitive strategies, and the technological trends driving this genetic-targeted pharmaceutical sector.

Market Overview

The global Nucleic Acid-based Therapy market is predicted to grow from US$ 13090 million in 2025 to US$ 16980 million in 2032, representing a compound annual growth rate (CAGR) of 3.9% from 2026 to 2032.

Product Definition

Nucleic acid drugs, also known as nucleic acid-based therapeutics, are a class of pharmaceuticals designed to treat various diseases by targeting specific genes or genetic processes within the human body. They are distinct from traditional small molecule drugs and instead rely on nucleic acids, which are the building blocks of genetic information. Nucleic acid drugs encompass various types of pharmaceuticals that use nucleic acids, such as DNA or RNA, as their active components to target specific genes or genetic processes.

Regional Market Analysis

• United States: The market for Nucleic Acid-based Therapy is estimated to experience growth from 2025 through 2032.
• China: The market for Nucleic Acid-based Therapy is estimated to experience growth from 2025 through 2032.
• Europe: The market for Nucleic Acid-based Therapy is estimated to experience growth from 2025 through 2032.

Report Scope and Methodology

LPI (LP Information)' newest research report, the “Nucleic Acid-based Therapy Industry Forecast,” looks at past sales and reviews total world Nucleic Acid-based Therapy sales in 2025, providing a comprehensive analysis by region and market sector of projected Nucleic Acid-based Therapy sales for 2026 through 2032. With Nucleic Acid-based Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acid-based Therapy industry.

This Insight Report provides a comprehensive analysis of the global Nucleic Acid-based Therapy landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue
• Market share
• Latest development
• M&A activity

Furthermore, this report analyses the strategies of leading global companies with a focus on:

• Nucleic Acid-based Therapy portfolios and capabilities
• Market entry strategies
• Market positions
• Geographic footprints

To better understand these firms’ unique position in an accelerating global Nucleic Acid-based Therapy market, the report evaluates key market trends, drivers, and affecting factors shaping the global outlook. The study breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acid-based Therapy market. The report presents a comprehensive overview, market shares, and growth opportunities of the Nucleic Acid-based Therapy market by product type, application, key players, and key regions and countries.

Market Segmentation

By Type

• Antisense Oligonucleotides (ASO)
• siRNA
• mRNA

By Application

• Neuromuscular Diseases
• hATTR
• COVID-19
• Other

By Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Key Market Dynamics

Global key Nucleic Acid-based Therapy players include Sarepta Therapeutics, Ionis Pharmaceuticals, Alnylam, Biogen, and Nippon Shinyaku. In terms of revenue, the global two largest companies occupied a significant share in 2025.

Profiled Companies

The following companies have been selected based on inputs gathered from primary experts and an analysis of the company's coverage, product portfolio, and market penetration:

• Sarepta Therapeutics
• Ionis Pharmaceuticals
• Alnylam
• Biogen
• Nippon Shinyaku
• Sobi
• Novartis
• BioNTech
• Pfizer
• Moderna Therapeutics
• Jazz Pharmaceuticals
• CureVac
• Regulus Therapeutics
• ProQR
• Secarna
• MiNA Therapeutics
• Sylentis
• Arrowhead
• Silence Therapeutics
• Dicerna

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Nucleic Acid-based Therapy Market Size (2021-2032)

    • 2.1.2 Nucleic Acid-based Therapy Market Size CAGR by Region (2021 VS 2025 VS 2032)

    • 2.1.3 World Current & Future Analysis for Nucleic Acid-based Therapy by Country/Region (2021, 2025 & 2032)

  • 2.2 Nucleic Acid-based Therapy Segment by Type

    • 2.2.1 Antisense Oligonucleotides (ASO)

    • 2.2.2 siRNA

    • 2.2.3 mRNA

    • 2.2.4 Nucleic Acid-based Therapy Market Size by Type

      • 2.2.4.1 Nucleic Acid-based Therapy Market Size CAGR by Type (2021 VS 2025 VS 2032)
      • 2.2.4.2 Global Nucleic Acid-based Therapy Market Size Market Share by Type (2021-2026)

  • 2.3 Nucleic Acid-based Therapy Segment by Application

    • 2.3.1 Neuromuscular Diseases

    • 2.3.2 hATTR

    • 2.3.3 COVID-19

    • 2.3.4 Other

    • 2.3.5 Nucleic Acid-based Therapy Market Size by Application

      • 2.3.5.1 Nucleic Acid-based Therapy Market Size CAGR by Application (2021 VS 2025 VS 2032)
      • 2.3.5.2 Global Nucleic Acid-based Therapy Market Size Market Share by Application (2021-2026)

• 3 Nucleic Acid-based Therapy Market Size by Player

  • 3.1 Nucleic Acid-based Therapy Market Size Market Share by Player

    • 3.1.1 Global Nucleic Acid-based Therapy Revenue by Player (2021-2026)

    • 3.1.2 Global Nucleic Acid-based Therapy Revenue Market Share by Player (2021-2026)

  • 3.2 Global Nucleic Acid-based Therapy Key Players Head office and Products Offered

  • 3.3 Market Concentration Rate Analysis

    • 3.3.1 Competition Landscape Analysis

    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.4 New Products and Potential Entrants

  • 3.5 Mergers & Acquisitions, Expansion

• 4 Nucleic Acid-based Therapy by Region

  • 4.1 Nucleic Acid-based Therapy Market Size by Region (2021-2026)

  • 4.2 Global Nucleic Acid-based Therapy Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Nucleic Acid-based Therapy Market Size Growth (2021-2026)

  • 4.4 APAC Nucleic Acid-based Therapy Market Size Growth (2021-2026)

  • 4.5 Europe Nucleic Acid-based Therapy Market Size Growth (2021-2026)

  • 4.6 Middle East & Africa Nucleic Acid-based Therapy Market Size Growth (2021-2026)

• 5 Americas

  • 5.1 Americas Nucleic Acid-based Therapy Market Size by Country (2021-2026)

  • 5.2 Americas Nucleic Acid-based Therapy Market Size by Type (2021-2026)

  • 5.3 Americas Nucleic Acid-based Therapy Market Size by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Nucleic Acid-based Therapy Market Size by Region (2021-2026)

  • 6.2 APAC Nucleic Acid-based Therapy Market Size by Type (2021-2026)

  • 6.3 APAC Nucleic Acid-based Therapy Market Size by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

• 7 Europe

  • 7.1 Europe Nucleic Acid-based Therapy Market Size by Country (2021-2026)

  • 7.2 Europe Nucleic Acid-based Therapy Market Size by Type (2021-2026)

  • 7.3 Europe Nucleic Acid-based Therapy Market Size by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Nucleic Acid-based Therapy by Region (2021-2026)

  • 8.2 Middle East & Africa Nucleic Acid-based Therapy Market Size by Type (2021-2026)

  • 8.3 Middle East & Africa Nucleic Acid-based Therapy Market Size by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Global Nucleic Acid-based Therapy Market Forecast

  • 10.1 Global Nucleic Acid-based Therapy Forecast by Region (2027-2032)

    • 10.1.1 Global Nucleic Acid-based Therapy Forecast by Region (2027-2032)

    • 10.1.2 Americas Nucleic Acid-based Therapy Forecast

    • 10.1.3 APAC Nucleic Acid-based Therapy Forecast

    • 10.1.4 Europe Nucleic Acid-based Therapy Forecast

    • 10.1.5 Middle East & Africa Nucleic Acid-based Therapy Forecast

  • 10.2 Americas Nucleic Acid-based Therapy Forecast by Country (2027-2032)

    • 10.2.1 United States Market Nucleic Acid-based Therapy Forecast

    • 10.2.2 Canada Market Nucleic Acid-based Therapy Forecast

    • 10.2.3 Mexico Market Nucleic Acid-based Therapy Forecast

    • 10.2.4 Brazil Market Nucleic Acid-based Therapy Forecast

  • 10.3 APAC Nucleic Acid-based Therapy Forecast by Region (2027-2032)

    • 10.3.1 China Nucleic Acid-based Therapy Market Forecast

    • 10.3.2 Japan Market Nucleic Acid-based Therapy Forecast

    • 10.3.3 Korea Market Nucleic Acid-based Therapy Forecast

    • 10.3.4 Southeast Asia Market Nucleic Acid-based Therapy Forecast

    • 10.3.5 India Market Nucleic Acid-based Therapy Forecast

    • 10.3.6 Australia Market Nucleic Acid-based Therapy Forecast

  • 10.4 Europe Nucleic Acid-based Therapy Forecast by Country (2027-2032)

    • 10.4.1 Germany Market Nucleic Acid-based Therapy Forecast

    • 10.4.2 France Market Nucleic Acid-based Therapy Forecast

    • 10.4.3 UK Market Nucleic Acid-based Therapy Forecast

    • 10.4.4 Italy Market Nucleic Acid-based Therapy Forecast

    • 10.4.5 Russia Market Nucleic Acid-based Therapy Forecast

  • 10.5 Middle East & Africa Nucleic Acid-based Therapy Forecast by Region (2027-2032)

    • 10.5.1 Egypt Market Nucleic Acid-based Therapy Forecast

    • 10.5.2 South Africa Market Nucleic Acid-based Therapy Forecast

    • 10.5.3 Israel Market Nucleic Acid-based Therapy Forecast

    • 10.5.4 Turkey Market Nucleic Acid-based Therapy Forecast

  • 10.6 Global Nucleic Acid-based Therapy Forecast by Type (2027-2032)

  • 10.7 Global Nucleic Acid-based Therapy Forecast by Application (2027-2032)

    • 10.7.1 GCC Countries Market Nucleic Acid-based Therapy Forecast

• 11 Key Players Analysis

  • 11.1 Sarepta Therapeutics

    • 11.1.1 Sarepta Therapeutics Company Information

    • 11.1.2 Sarepta Therapeutics Nucleic Acid-based Therapy Product Offered

    • 11.1.3 Sarepta Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.1.4 Sarepta Therapeutics Main Business Overview

    • 11.1.5 Sarepta Therapeutics Latest Developments

  • 11.2 Ionis Pharmaceuticals

    • 11.2.1 Ionis Pharmaceuticals Company Information

    • 11.2.2 Ionis Pharmaceuticals Nucleic Acid-based Therapy Product Offered

    • 11.2.3 Ionis Pharmaceuticals Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.2.4 Ionis Pharmaceuticals Main Business Overview

    • 11.2.5 Ionis Pharmaceuticals Latest Developments

  • 11.3 Alnylam

    • 11.3.1 Alnylam Company Information

    • 11.3.2 Alnylam Nucleic Acid-based Therapy Product Offered

    • 11.3.3 Alnylam Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.3.4 Alnylam Main Business Overview

    • 11.3.5 Alnylam Latest Developments

  • 11.4 Biogen

    • 11.4.1 Biogen Company Information

    • 11.4.2 Biogen Nucleic Acid-based Therapy Product Offered

    • 11.4.3 Biogen Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.4.4 Biogen Main Business Overview

    • 11.4.5 Biogen Latest Developments

  • 11.5 Nippon Shinyaku

    • 11.5.1 Nippon Shinyaku Company Information

    • 11.5.2 Nippon Shinyaku Nucleic Acid-based Therapy Product Offered

    • 11.5.3 Nippon Shinyaku Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.5.4 Nippon Shinyaku Main Business Overview

    • 11.5.5 Nippon Shinyaku Latest Developments

  • 11.6 Sobi

    • 11.6.1 Sobi Company Information

    • 11.6.2 Sobi Nucleic Acid-based Therapy Product Offered

    • 11.6.3 Sobi Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.6.4 Sobi Main Business Overview

    • 11.6.5 Sobi Latest Developments

  • 11.7 Novartis

    • 11.7.1 Novartis Company Information

    • 11.7.2 Novartis Nucleic Acid-based Therapy Product Offered

    • 11.7.3 Novartis Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.7.4 Novartis Main Business Overview

    • 11.7.5 Novartis Latest Developments

  • 11.8 BioNTech

    • 11.8.1 BioNTech Company Information

    • 11.8.2 BioNTech Nucleic Acid-based Therapy Product Offered

    • 11.8.3 BioNTech Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.8.4 BioNTech Main Business Overview

    • 11.8.5 BioNTech Latest Developments

  • 11.9 Pfizer

    • 11.9.1 Pfizer Company Information

    • 11.9.2 Pfizer Nucleic Acid-based Therapy Product Offered

    • 11.9.3 Pfizer Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.9.4 Pfizer Main Business Overview

    • 11.9.5 Pfizer Latest Developments

  • 11.10 Moderna Therapeutics

    • 11.10.1 Moderna Therapeutics Company Information

    • 11.10.2 Moderna Therapeutics Nucleic Acid-based Therapy Product Offered

    • 11.10.3 Moderna Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.10.4 Moderna Therapeutics Main Business Overview

    • 11.10.5 Moderna Therapeutics Latest Developments

  • 11.11 Jazz Pharmaceuticals

    • 11.11.1 Jazz Pharmaceuticals Company Information

    • 11.11.2 Jazz Pharmaceuticals Nucleic Acid-based Therapy Product Offered

    • 11.11.3 Jazz Pharmaceuticals Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.11.4 Jazz Pharmaceuticals Main Business Overview

    • 11.11.5 Jazz Pharmaceuticals Latest Developments

  • 11.12 CureVac

    • 11.12.1 CureVac Company Information

    • 11.12.2 CureVac Nucleic Acid-based Therapy Product Offered

    • 11.12.3 CureVac Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.12.4 CureVac Main Business Overview

    • 11.12.5 CureVac Latest Developments

  • 11.13 Regulus Therapeutics

    • 11.13.1 Regulus Therapeutics Company Information

    • 11.13.2 Regulus Therapeutics Nucleic Acid-based Therapy Product Offered

    • 11.13.3 Regulus Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.13.4 Regulus Therapeutics Main Business Overview

    • 11.13.5 Regulus Therapeutics Latest Developments

  • 11.14 ProQR

    • 11.14.1 ProQR Company Information

    • 11.14.2 ProQR Nucleic Acid-based Therapy Product Offered

    • 11.14.3 ProQR Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.14.4 ProQR Main Business Overview

    • 11.14.5 ProQR Latest Developments

  • 11.15 Secarna

    • 11.15.1 Secarna Company Information

    • 11.15.2 Secarna Nucleic Acid-based Therapy Product Offered

    • 11.15.3 Secarna Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.15.4 Secarna Main Business Overview

    • 11.15.5 Secarna Latest Developments

  • 11.16 MiNA Therapeutics

    • 11.16.1 MiNA Therapeutics Company Information

    • 11.16.2 MiNA Therapeutics Nucleic Acid-based Therapy Product Offered

    • 11.16.3 MiNA Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.16.4 MiNA Therapeutics Main Business Overview

    • 11.16.5 MiNA Therapeutics Latest Developments

  • 11.17 Sylentis

    • 11.17.1 Sylentis Company Information

    • 11.17.2 Sylentis Nucleic Acid-based Therapy Product Offered

    • 11.17.3 Sylentis Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.17.4 Sylentis Main Business Overview

    • 11.17.5 Sylentis Latest Developments

  • 11.18 Arrowhead

    • 11.18.1 Arrowhead Company Information

    • 11.18.2 Arrowhead Nucleic Acid-based Therapy Product Offered

    • 11.18.3 Arrowhead Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.18.4 Arrowhead Main Business Overview

    • 11.18.5 Arrowhead Latest Developments

  • 11.19 Silence Therapeutics

    • 11.19.1 Silence Therapeutics Company Information

    • 11.19.2 Silence Therapeutics Nucleic Acid-based Therapy Product Offered

    • 11.19.3 Silence Therapeutics Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.19.4 Silence Therapeutics Main Business Overview

    • 11.19.5 Silence Therapeutics Latest Developments

  • 11.20 Dicerna

    • 11.20.1 Dicerna Company Information

    • 11.20.2 Dicerna Nucleic Acid-based Therapy Product Offered

    • 11.20.3 Dicerna Nucleic Acid-based Therapy Revenue, Gross Margin and Market Share (2021-2026)

    • 11.20.4 Dicerna Main Business Overview

    • 11.20.5 Dicerna Latest Developments

• 12 Research Findings and Conclusion